{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T16:39:47Z","timestamp":1794328787821,"version":"4.9.0"},"reference-count":33,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T00:00:00Z","timestamp":1736553600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"accepted":{"date-parts":[[2024,9,11]]},"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Myasthenia gravis (MG) is an autoimmune disorder affecting neuromuscular junctions, leading to fluctuating muscle weakness. While many patients respond well to standard immunosuppression, a substantial subgroup faces ongoing disease activity. Emerging treatments such as complement factor C5 inhibition (C5IT) and neonatal Fc receptor (FcRn) antagonism hold promise for these patients. However, the current landscape is hindered by a paucity of comparative data that is crucial for treatment decisions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aims to compare the effectiveness and safety of C5IT and FcRn antagonists in a real-world setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective analysis of 153\u2009MG patients from 8 German specialised MG centres receiving either C5IT (26 eculizumab, 80 ravulizumab) or efgartigimod (47 patients) was conducted. Propensity score matching (PSM) was employed to compare changes in MG-specific outcome parameters within the first 6\u2009months after treatment initiation, along with safety profiles and concomitant MG therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Both treatment strategies led to rapid clinical improvements and substantial reductions in prednisolone doses. However, insufficient response was noted in 20%\u201349.1% of patients based on Quantitative MG and MG Activities of Daily Living (MG-ADL) scores. We did not identify any new safety concerns. After PSM, 40 patients remained in each group. In both cohorts, reductions in MG-ADL as prespecified primary study endpoint were comparable. Moreover, analyses of secondary outcome parameters demonstrated similar results for C5IT versus FcRn.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In contrast to current meta-analyses and indirect comparisons of clinical trial data, our real-world study demonstrates comparable efficacy and safety of C5IT and FcRn antagonism in MG.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jnnp-2024-334404","type":"journal-article","created":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T13:20:26Z","timestamp":1736601626000},"page":"310-321","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":34,"title":["C5 complement inhibition versus FcRn modulation in generalised myasthenia gravis"],"prefix":"10.1136","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0015-8484","authenticated-orcid":false,"given":"Niklas","family":"Huntemann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Gerischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meret","family":"Herdick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6048-7143","authenticated-orcid":false,"given":"Christopher","family":"Nelke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5306-7880","authenticated-orcid":false,"given":"Frauke","family":"Stascheit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menekse","family":"\u00d6zt\u00fcrk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina B","family":"Schroeter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Lehnerer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maike","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Schubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Schneider-Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Pfeuffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidrun H","family":"Kr\u00e4mer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz Felix","family":"Konen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8550-335X","authenticated-orcid":false,"given":"Thomas","family":"Skripuletz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Pawlitzki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Glaubitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Zsch\u00fcntzsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Scherwietes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Totzeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Hagenacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven G","family":"Meuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7233-5342","authenticated-orcid":false,"given":"Andreas","family":"Meisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Ruck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,1,11]]},"reference":[{"key":"2025032404000934000_96.4.310.1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0079-y"},{"key":"2025032404000934000_96.4.310.2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.20950"},{"key":"2025032404000934000_96.4.310.3","doi-asserted-by":"crossref","unstructured":"Schneider-Gold C , Hagenacker T , Melzer N , et al . Understanding the burden of refractory myasthenia gravis. Ther Adv Neurol Disord 2019;12. doi:10.1177\/1756286419832242","DOI":"10.1177\/1756286419832242"},{"key":"2025032404000934000_96.4.310.4","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-022-02448-4"},{"key":"2025032404000934000_96.4.310.5","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2022-330519"},{"key":"2025032404000934000_96.4.310.6","doi-asserted-by":"publisher","DOI":"10.1586\/1744666X.4.1.43"},{"key":"2025032404000934000_96.4.310.7","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30369-1"},{"key":"2025032404000934000_96.4.310.8","doi-asserted-by":"crossref","unstructured":"Vu T , Meisel A , Mantegazza R , et al . Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis. NEJM Evid 2022;1. doi:10.1056\/EVIDoa2100066","DOI":"10.1056\/EVIDoa2100066"},{"key":"2025032404000934000_96.4.310.9","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00080-7"},{"key":"2025032404000934000_96.4.310.10","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(21)00159-9"},{"key":"2025032404000934000_96.4.310.11","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00077-7"},{"key":"2025032404000934000_96.4.310.12","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15872"},{"key":"2025032404000934000_96.4.310.13","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2021-328665"},{"key":"2025032404000934000_96.4.310.14","first-page":"307","article-title":"S2k-Leitlinie: Diagnostik und Therapie myasthener Syndrome","volume":"6","author":"Meisel","year":"2023","journal-title":"DG Neurologie"},{"key":"2025032404000934000_96.4.310.15","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00145-3"},{"key":"2025032404000934000_96.4.310.16","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.52.7.1487"},{"key":"2025032404000934000_96.4.310.17","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.596382","article-title":"Outcome Measures in Clinical Trials of Patients With Myasthenia Gravis","volume":"11","author":"Thomsen","year":"2020","journal-title":"Front Neurol"},{"key":"2025032404000934000_96.4.310.18","first-page":"e1617","article-title":"Patient-acceptable symptom states in myasthenia gravis","volume":"95","author":"Mendoza","year":"2020","journal-title":"Neurology (ECronicon)"},{"key":"2025032404000934000_96.4.310.19","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51376"},{"key":"2025032404000934000_96.4.310.20","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26447"},{"key":"2025032404000934000_96.4.310.21","doi-asserted-by":"publisher","DOI":"10.3233\/JND-200584"},{"key":"2025032404000934000_96.4.310.22","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.52051"},{"key":"2025032404000934000_96.4.310.23","doi-asserted-by":"crossref","unstructured":"Murai H , Suzuki S , Hasebe M , et al . Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: interim analysis of post-marketing surveillance. Ther Adv Neurol Disord 2021;14. doi:10.1177\/17562864211001995","DOI":"10.1177\/17562864211001995"},{"key":"2025032404000934000_96.4.310.24","doi-asserted-by":"crossref","unstructured":"Dion\u00edsio JM , Ambrose P , Burke G , et al . Efgartigimod efficacy and safety in refractory myasthenia gravis - uk\u2019s first real-world experience. Neurology [Preprint]. doi:10.1101\/2024.01.31.24302082","DOI":"10.1101\/2024.01.31.24302082"},{"key":"2025032404000934000_96.4.310.25","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16189","article-title":"Efgartigimod in generalized myasthenia gravis: A real\u2010life experience at a national reference center","volume":"31","author":"Frangiamore","year":"2024","journal-title":"Euro J of Neurology"},{"key":"2025032404000934000_96.4.310.26","doi-asserted-by":"crossref","DOI":"10.1212\/CPJ.0000000000200276","article-title":"Therapeutic Responses to Efgartigimod for Generalized Myasthenia Gravis in Japan","volume":"14","author":"Suzuki","year":"2024","journal-title":"Neurol Clin Pract"},{"key":"2025032404000934000_96.4.310.27","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27974"},{"key":"2025032404000934000_96.4.310.28","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12293-5"},{"key":"2025032404000934000_96.4.310.29","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-024-01062-7"},{"key":"2025032404000934000_96.4.310.30","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.790834","article-title":"Different Monoclonal Antibodies in Myasthenia Gravis: A Bayesian Network Meta-Analysis","volume":"12","author":"Song","year":"2021","journal-title":"Front Pharmacol"},{"key":"2025032404000934000_96.4.310.31","unstructured":"Steen C Celico L , Spaepen E , et al . Efgartigimod and Ravulizumab for Treating Acetylcholine Receptor Auto-Antibody-Positive (AChR-Ab+) Generalized Myasthenia Gravis: Indirect Treatment Comparison. Adv Ther, 2024."},{"key":"2025032404000934000_96.4.310.32","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10891-1"},{"key":"2025032404000934000_96.4.310.33","first-page":"865","article-title":"Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals","volume":"82","author":"Menon","year":"2022","journal-title":"Drugs (Abingdon Engl)"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2024-334404","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T07:10:51Z","timestamp":1742800251000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2024-334404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,11]]},"references-count":33,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,3,24]]},"published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1136\/jnnp-2024-334404"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2024-334404","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,11]]}}}